Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul;26(7):e13915.
doi: 10.1111/obr.13915. Epub 2025 Apr 4.

Hyperphagia in Bardet-Biedl syndrome: Pathophysiology, burden, and management

Affiliations
Review

Hyperphagia in Bardet-Biedl syndrome: Pathophysiology, burden, and management

Philip L Beales et al. Obes Rev. 2025 Jul.

Abstract

Bardet-Biedl syndrome (BBS) is a rare, genetically heterogeneous, and highly pleiotropic autosomal recessive ciliopathy. Patients typically present with early loss of vision, hyperphagia, severe obesity, learning difficulties, and renal dysfunction. In patients with BBS, dysfunction of the immotile primary cilia in the hypothalamic melanocortin-4 receptor (MC4R) pathway responsible for controlling energy balance, hunger, and satiety results in severe hyperphagia manifesting in food-seeking behaviors that drive the development of obesity early in childhood. These behaviors have negative impacts on many areas of the lives of patients with BBS and their families/caregivers, including sleep, mood, school/work, and social/family relationships. Additionally, many patients feel stigmatized due to their hyperphagia-associated food-seeking behaviors and the resulting obesity, which exacerbates the impacts of hyperphagia on quality of life. Early identification and management of hyperphagia in patients with BBS is key: mitigating food-seeking and weight gain can improve quality of life and reduce the risk of metabolic and cardiovascular diseases that is increased in patients with BBS. Until recently, the only treatment strategies available were lifestyle and diet modifications. However, targeted treatment with the novel MC4R agonist setmelanotide now offers an effective management option to reduce hyperphagia and weight in patients with BBS, improving overall health and quality of life.

Keywords: Bardet–Biedl syndrome; MC4R pathway; hyperphagia; obesity.

PubMed Disclaimer

Conflict of interest statement

PLB has participated on an advisory board for BBS UK; has participated in a webinar and symposium hosted by Rhythm Therapeutics; and serves as CEO of Axovia Therapeutics, a BBS‐focused gene therapy company. MC has served as a principal investigator for Rhythm Pharmaceuticals; has received funding from the German Federal Ministry of Education and Research (BMBF); has received consulting fees from Rhythm Pharmaceuticals; and has received honoraria from Alexion, Canon Medical Systems, Desitin, and Rhythm Pharmaceuticals. AMH has served as a principal nvestigator for Acadia Pharmaceuticals, Eli Lilly, Levo Therapeutics, and Rhythm Pharmaceuticals; has received grant funding from the Canadian Institutes of Health Research (CIHR), Weston Family Foundation, and Women and Children's Health Research Institute (WCHRI); has received consulting fees from Novo Nordisk Canada, Pfizer Canada, and Rhythm Pharmaceuticals; has received honoraria from Rhythm Pharmaceuticals; and has participated on an advisory board for Novo Nordisk Canada and Rhythm Pharmaceuticals. JM has received research funding from Harmony Biosciences, Rhythm Pharmaceuticals, and Soleno Therapeutics. AHS has received grants from Rhythm Pharmaceuticals and Soleno Therapeutics; has received consulting fees from LG Chem Ltd, Radius Health, Inc., Rhythm Pharmaceuticals, and Saniona A/S; and has received honoraria from Rhythm Pharmaceuticals. DV has received honoraria and support for attending meetings and/or travel from Rhythm Pharmaceuticals. MZ has received support for attending meetings and/or travel from Rhythm Pharmaceuticals. HD has received consulting fees from Gensight, Novartis, Rhythm Pharmaceuticals, and Sparrington.

Figures

FIGURE 1
FIGURE 1
The role of the primary cilia in leptin signaling and control of hyperphagia. The BBSome is involved in cilia function and leptin receptor signaling. Patients with BBS have an impaired MC4R pathway, which can be caused by a variant of one or more of the genes that encode the BBSome proteins (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, BBS9, BBS18). This can cause both dysfunction of the cilia and disruption of leptin receptor signaling. BBS6, BBS10, and BBS12 are thought to be chaperone proteins involved in BBSome assembly, while the role of other proteins has yet to be determined. α‐MSH, alpha‐melanocyte‐stimulating hormone; BBS, Bardet–Biedl syndrome; LEPR, leptin receptor; MC4R, melanocortin‐4 receptor; POMC, pro‐opiomelanocortin.

References

    1. Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet‐Biedl syndrome—now and in the future. Front Pediatr. 2018;6:23. doi:10.3389/fped.2018.00023 - DOI - PMC - PubMed
    1. De Vries TI, van Haelst MM. Ciliary disturbances in syndromal and non‐syndromal obesity. J Ped Genet. 2014;3:79‐88. doi:10.3233/PGE-14085 - DOI - PMC - PubMed
    1. Forsythe E, Beales PL. Bardet‐Biedl syndrome. Eur J Hum Genet. 2013;21(1):8‐13. doi:10.1038/ejhg.2012.115 - DOI - PMC - PubMed
    1. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet‐Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437‐446. doi:10.1136/jmg.36.6.437 - DOI - PMC - PubMed
    1. Sherafat‐Kazemzadeh R, Ivey L, Kahn SR, et al. Hyperphagia among patients with Bardet‐Biedl syndrome. Pediatr Obes. 2013;8(5):e64‐e67. doi:10.1111/j.2047-6310.2013.00182.x - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources